These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8083102)

  • 41. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
    Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
    Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation.
    Choy H; Yee L; Cole BF
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):38-44. PubMed ID: 8643969
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.
    Ready N; Karaseva NA; Orlov SV; Luft AV; Popovych O; Holmlund JT; Wood BA; Leopold L
    J Thorac Oncol; 2011 Apr; 6(4):781-5. PubMed ID: 21289522
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Radiation-enhancing effect of sodium glycididazole in patients suffering from non-small cell lung cancer with multiple brain metastases: A randomized, placebo-controlled study.
    Zeng YC; Wu R; Xing R; Chi F; Wang SL; Chen XD; Xuan Y; Wu LN; Duan QY; Tang MY; Niu N; Sun YN; Fan GL; Wang HM
    Cancer Radiother; 2016 May; 20(3):187-92. PubMed ID: 27052296
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of unfavorable factors on outcomes among inoperable stage II-IV Nonsmall cell lung cancer patients treated with proton therapy.
    Zhu HJ; Nichols RC; Henderson RH; Morris CG; Flampouri S; Pham DC; Klassen CL; Seeram V; Cury JD; Jones L; McGee L; Hoppe BS
    Acta Oncol; 2019 Mar; 58(3):313-319. PubMed ID: 30656994
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
    Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.
    Sause W; Kolesar P; Taylor S IV; Johnson D; Livingston R; Komaki R; Emami B; Curran W; Byhardt R; Dar AR; Turrisi A
    Chest; 2000 Feb; 117(2):358-64. PubMed ID: 10669675
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancer.
    Buccheri G; Ferrigno D; Rosso A
    Cancer; 1993 Sep; 72(5):1564-72. PubMed ID: 8394198
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial.
    Movsas B; Hu C; Sloan J; Bradley J; Komaki R; Masters G; Kavadi V; Narayan S; Michalski J; Johnson DW; Koprowski C; Curran WJ; Garces YI; Gaur R; Wynn RB; Schallenkamp J; Gelblum DY; MacRae RM; Paulus R; Choy H
    JAMA Oncol; 2016 Mar; 2(3):359-67. PubMed ID: 26606200
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adoptive immunotherapy for nonsmall cell lung carcinoma. A fourth treatment modality, complicated radiation sensitizer, or none of the above.
    Karp DD; Atkins MB
    Cancer; 1996 Jul; 78(2):195-8. PubMed ID: 8673991
    [No Abstract]   [Full Text] [Related]  

  • 51. Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trials.
    Fossella FV
    Semin Oncol; 1999 Oct; 26(5 Suppl 16):17-23; discussion 41-2. PubMed ID: 10585004
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Concurrent chemoradiotherapy with cisplatin and vinorelbine for stage III non-small cell lung cancer.
    Naito Y; Kubota K; Nihei K; Fujii T; Yoh K; Niho S; Goto K; Ohmatsu H; Saijo N; Nishiwaki Y
    J Thorac Oncol; 2008 Jun; 3(6):617-22. PubMed ID: 18520801
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A randomised clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III non-small cell lung cancer.
    Cakir S; Egehan I
    Lung Cancer; 2004 Mar; 43(3):309-16. PubMed ID: 15165089
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Results of multifield conformal radiation therapy of nonsmall-cell lung carcinoma using multileaf collimation beams.
    Bahri S; Flickinger JC; Kalend AM; Deutsch M; Belani CP; Sciurba FC; Luketich JD; Greenberger JS
    Radiat Oncol Investig; 1999; 7(5):297-308. PubMed ID: 10580899
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Daily paclitaxel and thoracic radiation therapy for non-small cell lung cancer: preliminary results.
    Rathmann J; Leopold KA; Rigas JR
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):130-5. PubMed ID: 10210552
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase II trial of radiochemotherapy with daily carboplatin, after induction chemotherapy (carboplatin and etoposide), in locally advanced nonsmall-cell lung cancer: final analysis.
    Bardet E; Rivière A; Charloux A; Spaeth D; Ducoloné A; Le Groumellec A; Pellae-Cosset B; Henry-Amar M; Douillard JY
    Int J Radiat Oncol Biol Phys; 1997 Apr; 38(1):163-8. PubMed ID: 9212019
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mitomycin, cisplatin, and vindesine followed by radiotherapy combined with cisplatin in stage III nonsmall cell lung cancer: long-term results.
    Tejedor M; Valerdi JJ; López R; Domínguez MA; Arias F; Illarramendi JJ; Martínez E
    Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):813-8. PubMed ID: 7860393
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase II study of celecoxib with docetaxel chemoradiotherapy followed by consolidation chemotherapy docetaxel plus cisplatin with maintenance celecoxib in inoperable stage III nonsmall cell lung cancer.
    Takhar H; Singhal N; Mislang A; Kumar R; Kim L; Selva-Nayagam S; Pittman K; Karapetis C; Borg M; Olver IN; Brown MP
    Asia Pac J Clin Oncol; 2018 Feb; 14(1):91-100. PubMed ID: 28840978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.